ReviewPsychological research2025
A primer on meta-awareness of mind wandering in schizotypy and schizophrenia.
Review in Psychological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During everyday life, our attention may drift away from immediate perceptual inputs to consider alternatives unrelated to the task at hand, which is known as mind wandering. At times, mind wandering may be accompanied by awareness of one's attention having deviated from the ongoing task, often referred to as meta-awareness. However, mind wandering can also occur without individuals immediately noticing that their attention is off task. Importantly, little is known about mind wandering and meta-awareness, including their underlying content in schizotypy and schizophrenia. Here, in this narrative review, we synthesise the existing literature on mind wandering across the schizotypy-schizophrenia continuum. In doing so, we present the main proposal that there would be lower levels of meta-awareness of mind wandering in patients with schizophrenia as compared to healthy controls. We expect that meta-awareness of mind wandering would be negatively associated with schizophrenia symptomatology and multidimensional schizotypy traits. We also recommend examining mind wandering content in patients with schizophrenia spectrum disorders, including links between multidimensional schizotypy and the contents of meta-awareness of mind wandering. Ultimately, we hope that our proposal will be empirically tested in future research and will provide a foundation to understand the diversity of mind wandering features in clinical populations as well as insights into potential new treatment avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.